Diário Oficial república federativa do brasil



Baixar 140.33 Kb.
Página3/3
Encontro11.06.2018
Tamanho140.33 Kb.
1   2   3

39- Hughes TP, Kaeda J, Branford, S et al. (for the International Randomised Study of Interferon versus STI571 (IRIS) Study Group). Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia. October 9, 2003, Volume 349, Number 15,:1423-1432.

40- Ilaria Jr. RL. Pathobiology of Lymphoid and Myeloid Blast Crisis and the Management Issues. The American Society of Hematology 47th Annual Meeting, December 10-13, 2005. Education Program Book: 188-194.

41- Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia. N Engl J Med, February 28, 2002, Vol. 346, No. 9,: 645-652.

42- Kantarjian HM et al. Imatinib mesylate (STI571) therapy for Philadelphia chromossome-positive chronic myelogenous leukemia in blast phase. Blood, 15 May 2002, Volume 99, Number 10: 3547-3553.

43- Kantarjian HM et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood, 1 September 2002, Volume 100, Number 5: 1590-1595.

44- Kantajian HM et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood, 1 January 2003, Volume 101, Number 1: 97-99.

45- Kantarjian HM. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, 15 January 2003, Volume 101, Number 2: 473-475.

46- Kantarjian H, O'Brien S, Cortes J et al , Survival Advantage with Imatinib Mesylate Therapy in Chronic- Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-a Failure and in Late CML-CP, Comparison with Historical Controls - Clinical Cancer Research, January 1, 2004, vol 10, 68-75.

47- Kantarjian H, Talpaz M, O´Brien S et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase myeloid leukemia. Blood, 15 April 2004; 103 (8): 2873-2878.

48- Kantarjian H, Cortes J, O'Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosomepositive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004; 104: 1979-1988.

49- Kantarjian H, Talpaz M, O´Brien S et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia - Comparison with historic experience. Cancer, 13 April 2005, Volume 103, Issue 10: 2099-2108.

50- Kantarjian HM, Talpaz M, O´Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J. Survival Benefit wiyh Imatinib Mesylate versus Interferon Alpha-Based Regimens in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia. Blood First Edition Paper, prepublished on line May 18, 2006; DOI 10.1182/blood-2006-02-004325. 27p. Copyright © 2006 American Society of Hematology.

51- Kantarjian HM, Pasquini R, Hamerschlak N et al – Dasatinib or high-dose imatinib for chronic-phase myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial - Blood, 15 June 2007 - volumw 109, number 12, 5143-5150.

52- Keam SJ - Dasatinibe na Leucemia Mielóide Crônica e na Leucemia Linfoblástica Aguda Positiva para o Cromossomo Philadelphia - reimpresso de BioDrugs 2008, vol.22, (1) : 59-69.

53- Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine. Published on line 23 July 2006; doi:10.1038/nm1446. 9p.

54- Krauser DS, Van Etten RA. Tyrosine Kinases as Targets for Cancer Therapy. N Engl J Med, July 14, 2005, Vol. 353, No. 2: 172-187.

55- Kreuzer KA, le Coutre P, Landt O, Na IK, Schwarz M, Schultheis K, Hochhaus A, Dörken B. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique.

http://link.springer.de/link/service/journals/00277/con-tents/03/00644/s00277-003-0644-yxh0…19/05/03.

56- Lange T, Deininger MWN. Residual Disease in Chronic Myeloid Leukemia after Induction of Molecular Remission. N Engl J Med. October 9, 2003. Volume 349, Number 15.:1483-1484. (Correspondence)

57- Lin F, Drummond M, O´Brien S, Cervantes F, Goldman J, Kaeda J. Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib. Blood, 1 August 2003, Volume 102, Number 3: 1143. (Correspondence)

58- Lin NU, Sarantopoulos S, Stone JR, Galinsky I, Stone RM, Deangelo DJ, Soiffer RJ. Fatal hepatic necrosis following imatinib mesylate therapy. 3455 Blood, 1 November 2003, Volume 102, Number 9: 3455-3456. (Correspondence)

59- Löwenberg B. Minimal Residual Disease in Chronic Myeloid Leukemia. October 9, 2003.Volume 349. Number 15:1399-1401.

60- Luzzatto L; Melo JV. Acquired resistance to imatinib mesylate: seletion por pre-exist mutant cells. Correspondence to the Editor. Blood, 1 August 2002, Vol. 100, No. 3: 1105-1106.

61- Luzzatto L et al. Imatinib: can one outwit chronic myeloid leukemia? http:www.haematologica.it/2002

62- Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood, 15 March 2003, Volume 101, Number 6: 2368-2373.

63- Marin D et al. The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations. Haematologica, September 2002, vol. 87(9): 980-989.

64- Marin D, Marktel S, Szydlo R et al. Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. Lancet , 23 August 2003, Volume 362, Number 9384. (letter).

65- Marktel S, Marin D, Foot N, Szydlo R, Bua M, Karadimitris A, de Melo VAS et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the ocurrence of additional cytogenetic abnormalities predictis disease progression. haematologica/journal of hematology, march 2003, vol. 88 (3): 260-267.

66- Melo JV. Resistance to imatinibe mesylate in CML: all BCR-ABL mutations "are created equal but some are more equal than others". Blood, 1 June 2003; 101 (11): 4231. (Correspondence)

67- Moen MD, McKeage K, Plosker GL, Siddiqui MAA. Imatinib - A Review of its Use in Chronic Myeloid Leukaemia. Drugs, 2007; 67 (2): 299-320.

68- NCCN - National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in OncologyTM. Chronic Myelogenous Leukemia. V.2.2007. http://www.nccn.org

69- NICE - National Institute for Clinical Excellence. Final Appraisal Determination: Imatinib for chronic myeloid leukaemia. Protocol: The effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase. July 2002. 14p. http://www.nice.org .uk

70- O'Brien S. New Data Suggest Twice the Standard Dose of Gleevec (Imatinib) May Be Even More Effective as Initial Therapy for Patients with Chronic Myeloid Leukemia. 38th Annual Meeting of the ASCO, 2002.

71- O´Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ et al. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. N Engl J Med, Vol. 348, No.11, March 13, 2003: 994-1004.

72- O'Brien SG, Deininger MWN. Imatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. Seminars in Hematology, (April), 2003, Vol 40, No 2, Suppl 2: 26-30.

73- O'Dwyer, ME et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood, 1 September 2002, Vol. 100, No. 5: 1628-1633.

74- O'Dwyer ME, Mauro MJ, Blasdel C, Farnsworth M, Kurilik G, Hsieh YC, Mori M, Druker, BJ. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CMLpatients treated with imatinib mesylate. Blood, 15 January 2004, Volume 103, Number 2: 451-455.

75- O´Hare TO et al. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood, 1 October 2007, Vol. 110, No. 7: 2242-2249.

76- Ohno R, Nakamura Y. Prediction of Response to Imatinib by cDNA Microarray Analysis. Seminars in Hematology, (April), 2003, Vol 40, No 2, Suppl 2: 42-49.

77- Olavarria E et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood, 15 May 2002, Volume 99, Number 10: 3861-3862.

78- Otazú I et al. A Rare, In-Frame BCR-ABL Fusion (e 13a3) in a Patient with in Aggressive Chronic Myeloid Leukemia. Acta Haematol 2002; 108: 150-153.

79- Otero L et al. The Impact of Additional Chromosomal Abnormalities in Response to Imatinib Mesylate Therapy for Chronic Myeloid Leukemia. Revista Brasileira de Cancerologia 2007; 53 (4): 405-410.

80- Peggs K, Mackinnon S. Imatinib Mesylate - The New Gold Standard for Treatment of Chronic Myeloid Leukemia. N Engl J Med, March 13, 2003, Vol. 348, No.11: 1048-1050.

81- Quintás-Cardama A, Cortes JE. Chronic Myeloid Leukemia: Diagnosis and Treatment. In: Tefferi A, Rajkumar SV, Kantarjian H. Neoplastic Hematology - Diagnosis and Treatment. Collection of symposium articles published in Mayo Clinic Proceedings. 2006 Mayo Foundation for Medical Education and Research. pp: 57-72.

82- Robert C, Spatz A, Faivre S, Armand JP, Raymond E. Tyrosine kinase inhibition and gray hair. The Lancet, 22 March 2003, Vol. 361, Number 9362. (Correspondence)

83- Roche-Lestienne C et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood, 1 August 2002, Vol. 100, No. 3: 1014-1018.

84- Rosti G, Trabacchi E, Bassi S, Bonifazi F, de Vivo A, Martinelli G, Alberti D et al. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. haematologica/journal of hematology, march 2003, vol. 88 (3): 256-259.

85- Rosti G, Testoni N, Martinelli G, Baccarani M. The Cytogenetic Response as a Surrogate Marker of Survival. Semin Hematol, 2003, 40 (suppl 2) 56-61.

86- Rosti G., Martinelli G, Bassi S, et al. Molecular response to imatinib in late chronic phase chronic myeloid leukemia. Blood.2004; 103: 2284-2290.

87- Roy L, Guilhot J, Krahnke T et al. Survival advantage from imatinib compared with the combination interferon-plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood, 1 September 2006, Vol. 108, No. 5: 1478-1484.

88- Rowe JM. Closing the gap in CML. Blood, 15 March 2007, Vol. 109, No. 6: 2271.

89- Rule SAJ et al. Managing cutaneous reactions to imatinib therapy. Blood, 1 November 2002, Vol. 100, No. 9: 3434 (Correspondence)

90- Rumpel M, Friedrich T, Deininger MWN. Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase. Blood, 1 June 2003; 101 (11): 4641-4643. (Correspondence)

91- Sawers CL et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 15 May 2002, Volume 99, Number 10: 3530-3539.

92- Sawyera CL. Resistance to imatinib: more and more mutations. Blood, 1 July 2003; 102 (1): 4. (Correspondence)

93- Schaich M; Schäkel K; Illmer T; Ehninger G; Bornhäuser M. Case Report: Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation. http://link.springer.de/link/service/journals/00277/contents/ 03/00643/s00277-003-0643-zxh0…19/05/03.

94- Schlaifer D et al. Severe Urticaria and Edema Reaction after STI-571 Treatment. 38th Annual Meeting of the ASCO, 2002. Abstract # 2634.

95- Schrover RJ et al. Prognosis of Patients with CML in Chronic Phase Post Interferon-Alpha Therapy Treated with Imatinib - A Survival Model. 38th Annual Meeting of the ASCO, 2002. Abstract # 2649.

96- Shah NP. Loss of Response to Imatinib: Mechanisms and Management. The American Society of Hematology 47th Annual Meeting, December 10-13, 2005. Education Program Book: 183-187.

97- Slavin S et al. Non-myeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Leukemia 2002. Global Organization Against Leukemia (GOAL). Florida-USA, September 19-22, 2002. (Proceedings)

98- Talpaz M et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 15 May 2002, Volume 99, Number 6: 1928-1936.

99- Talpaz M et al. Dasatinib in Imatinib-Resistant Philadelphia Chromosome-Positive Leukemias. N Engl J Med 2006; 354:2531-41.

100- Tipping AJ, Melo JV. Imatinib Mesylate in Combination With Other Chemotherapeutic Drugs: In Vitro Studies. Seminars in Hematology, (April), 2003, Vol 40, No 2, Suppl 2: 83-91.

101- Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D, Olavarria E et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood, 1 April 2002, Volume 99, Number 7: 2304-2309.

102- Warren E et al. The Clinical and Cost Effectiveness of Imatinib (Glivec, STI571) for Chronic Myeloid Leukaemia (CML). 38th Annual Meeting of the ASCO, 2002. Abstract # 1094.



103- Wolff NC, Richardson JA, Egorin M, Ilaria, Jr RL. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood, 15 June 2003, Vol. 101, No. 12: 5010-5013.

 

 


1   2   3


©aneste.org 2017
enviar mensagem

    Página principal